Table 3

Expression of PRL-3 in primary colorectal cancers with clinicopathological features

Case no.PRL-3 mRNA expression *P
Low expressionHigh expression
n%n%
Total17798(55.4)79(44.6)
SexP = 0.596
 Male11562(54.0)53(46.0)
 Female6236(58.1)26(41.9)
Age (years)P = 0.219
 68≤9549(51.6)46(48.4)
 67≥8249(59.8)33(40.2)
Histology P = 0.310
 Wel7343(58.9)30(41.1)
 Mod9649(51.0)47(49.0)
 Por/muc86(75.0)2(25.0)
Depth of invasion P = 0.093
 Tis/T13222(68.8)10(31.2)
 T2/T3/T414576(52.4)69(47.6)
Tumor sizeP = 0.247
 41 mm≤9046(51.1)44(48.9)
 40 mm≥8752(59.8)35(40.2)
Lymphatic invasionP = 0.173
 Ly (−)4730(63.8)17(36.2)
 Ly (+)13068(52.3)62(47.7)
Venous invasionP = 0.007 §
 V (−)6444(68.8)20(31.2)
 V (+)11354(47.8)59(52.2)
Metastasis
 Lymph node (−)12171(58.6)50(41.4)P = 0.193
 Lymph node (+)5627(48.2)29(51.8)
 Liver (−)14593(64.1)52(35.9)P < 0.001
 Liver (+)325(15.6)27(84.4)
 Lung (−)16897(57.7)71(42.3)P = 0.006 §
 Lung (+)91(11.1)8(88.9)
 Dissemination (−)17396(55.5)77(44.5)P = 0.827
 Dissemination (+)42(50.0)2(50.0)
  • * PRL-3positive cells were graded as showing high or low expression as described in the text.

  • According to the criterion of the General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus (13) along with the classification of the International-Union Against Cancer (14) .

  • Statistical analysis was performed by χ2 test. A P < 0.05 was regarded as statistically significant.

  • § P < 0.05.

  • P < 0.001.